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Volume 54, Number 4 Abstracts 1227Introduction and objectives: Few options exist for treating patients with
massive inferior vena cava (IVC) and iliofemoral deep vein thrombosis (DVT)
and a contraindication to thrombolysis.Wepresent five patientswhounderwent
IVC/iliac mechanical venous thrombectomy using a novel intravascular device.
Methods:During a 6-month period, five patients underwent mechan-
ical aspiration thrombectomy of IVC/iliac venous occlusion using the
Vortex Angiovac system. A 22F cannula was placed into the iliac venous
system via bilateral femoral cutdowns. The cannula was connected to a
venovenous bypass circuit, and thrombus was trapped in a separate filter
(Fig). Anticoagulated blood was returned to the patient via a right internal
jugular venous cannula. Open thrombectomy was performed of the bilateral
lower extremity veins.
Results: Five patients presented with acute (3 months) IVC throm-
bosis, manifested by phlegmasia in three or debilitating lower extremity
swelling in two. All patients had a contraindication to thrombolytic therapy.
Four patients had documented hypercoagulable states and a previously
placed IVC filter. IVC thrombectomy was successful in all five patients.
Intravascular ultrasound (IVUS) identified residual stenosis in four patients,
which were successfully treated with Wallstents. Mean procedure time was
389 minutes. Patients were discharged at an average of 8.5 days postopera-
tively on full anticoagulation. There were no deaths. Lower extremity edema
significantly improved in all patients. Follow-up computed tomography scan
at a mean of 72 days showed continued patency of the IVC in all patients.
Conclusions: The Vortex AngioVac provides a safe and effective
alternative method for treating massive acute (3 months) IVC thrombosis
in patients with a contraindication to thrombolysis.
Use of a Postoperative Insulin Protocol Decreases Wound Infection in
Diabetic Patients Undergoing Lower Extremity Bypass
Fuyuki Hirashima,1 Reshma Patel,1 Julie E. Adams,1 Peter W. Callas,2 Daniel J.
Bertges,1 Georg Steinthorsson,1 Janet McSorley,1 Andrew C. Stanley,1 1Fletcher
AllenHealth Care, Burlington, Vt; 2University of Vermont, Burlington, Vt
Introduction and objectives: Strict glucose control in patients undergo-
ing coronary bypass grafting has been shown to decrease infectious complica-
tions, arrhythmias, and death. Our objective was to determine if strict glucose
control reduced morbidity after lower extremity bypass (LEB).
Methods:Aprospective pilot study at a single institutionwithin theVascular
Study Group of New England was conducted from January 2009 to December
2010. Diabetic and nondiabetic patients undergoing LEB received an insulin
infusion for 3 days after surgery, with titration of blood glucose to 80 to 120
mg/dL. The study group of 104 patients was compared with a historic control
group of 189 patients from the preceding 2 years. Fisher exact test, t tests, and 2,
and logistic regression analyses were used to compare in-hospital morbidity. Strati-
fied analyses were conducted to determine if findings differed by the presence or
absence of diabetes.
Results: There was no difference between the insulin infusion group
and historical control group with regard to graft infection, myocardial
infarction, dysrhythmias, primary patency at discharge, or mortality rate.
Patients in the intravenous insulin group had significantly fewer wound
infections (4% vs 11%; odds ratio [OR], 0.32; 95% confidence interval [CI],
0.11-0.96; P  .047). This association was strengthened after adjusting for
potentially confounding baseline differences in gender, body mass index,
and smoking status (adjusted OR, 0.22; 95% CI, 0.06-0.84; P .03). When
Fig. Thrombus was trapped in a separate filter.stratified by presence of diabetes, wound infections were decreased in the
insulin infusion group (0 of 44 [0%] vs 9 of 90 [10%], P  .03.) There was
3
Ao statistically significant difference in wound infection between nondiabetic
ndividuals in the insulin infusion group and the control group.
Conclusions: Strict glucose control with a postoperative insulin infu-
ion protocol significantly decreased the incidence of postoperative wound
nfection in all diabetic individuals undergoing LEB. These previously
nreported findings from this single-institution prospective study warrant
urther multi-institutional investigation.
lood Transfusion is Associated With Increased Perioperative Surgical
ite Infection and Graft Failure in Lower Extremity Bypass
ze-Woei Tan,1 Jeffrey Kalish,1 Alik Farber,1 Naomi Hamburg,1 Robert
berhardt,1 Gheorghe Doros,1 Denis Rybin,1 Jen Eldrup-Jorgensen,2
hilip Goodney,3 Jack L. Cronenwett,3 1Vascular Study Group of New
ngland, Boston Medical Center, Boston, Mass; 2Maine Medical Center,
ortland, Me; 3Dartmouth-Hitchcock Medical Center, Lebanon, NH
Introduction and objectives: Packed red blood cell transfusion has
een postulated to increase morbidity andmortality after cardiac and general
urgical operations, but its effects after lower extremity bypass (LEB) have
ot been studied extensively. Most studies have focused on the perioperative
eriod, but long-term effects of transfusion have not been elucidated.
Methods: Using the Vascular Study Group of New England database
2003-2010), we examined 2582 consecutive infrainguinal LEB procedures
erformed by 71 surgeons at academic and community hospitals on patients
ith claudication and critical limb ischemia (CLI). Perioperative transfusionwas
ategorized as 0 units, 1 to 2 units, and 3 units. Patients who received 3
nits were case-matched for age, coronary artery disease, diabetes, and urgency
f revascularization with patients who received 1 to 2 or 0 units. Primary end
ointswere perioperative death, surgical site infection (SSI), andgraft patency at
ischarge, as well as mortality, SSI, and graft patency at 1 year.
Results: In the case-matched sample, 514 LEB patients (63%) received 0
nits, 194 (23.8%) received 1 to 2 units, and 108 (13.2%) received3 units of
acked red blood cells. Transfusion was associated with significantly higher
erioperative SSI and return to the operating room and with a significantly
ower discharge patency rate (Table). At 1 year, no significant differences existed
n mortality, SSI, or graft patency. In multivariate analysis, after controlling for
ndication of CLI vs claudication, transfusion was still associated with increased
erioperative SSI (P .006) and graft failure at discharge (P .0001).
Conclusions: Perioperative transfusion in patients undergoing LEB is
ssociated with increased SSI and perioperative graft failure. From this observa-
ional study, it appears transfusion does not have significant long-term conse-
uences, but its detrimental effects in the perioperative periodmust be weighed
arefully against the presumed benefits of blood replacement.
able. Patient characteristics and outcomes of transfusion
Characteristica
0 units 1-2 units 3 units
P(n 514) (n 194) (n 108)
Age, mean  SD,
years
73.4  10.7 73.3  11.1 74.6  10.8 .52
Proportion with
Critical limb
ischemia
410 (79.8) 176 (90.7) 100 (92.6) .0001
Diabetes mellitus 364 (70.8) 142 (73.2) 78 (72.2) .81
Coronary artery
disease
259 (50.4) 96 (49.5) 53 (49.1) .97
Great saphenous
vein
339 (66) 121 (62.4) 65 (60.2) .36
Perioperative SSI 20 (3.9) 15 (7.7) 16 (14.8) .0001
Graft patency at
discharge
487 (96.1) 178 (91.8) 89 (84) .0001
1-year outcomes
Mortality 59 (14.5) 28 (18.7) 17 (23.3) .12
SSI 22 (7.9) 14 (15.2) 4 (10.3) .12
Graft patency 232 (70.3) 85 (72.6) 32 (61.5) .34
D, Standard deviation;SSI, Surgical site infection
Data are shown as number (%) unless indicated otherwise.
ostPerDayofPatency:Long-termImplicationsofPatency andReinterven-
ions After Endovascular vs Surgical Lower Extremity Revascularizations
anish Mehta, Fariha Ramay, Sean P. Roddy, Paul B. Kreienberg, Yaron Stern-
ach, Philip S.K. Paty, John B. Taggert, Kathleen J. Ozsvath, Benjamin B. Chang,
hiraj M. Shah, R. Clement Darling III, The Vascular Group, Albany, NY
Introduction and objectives: Using an amortized cost model, we
rospectively evaluated the long-term costs associated with all initial and
einterventions of lower extremity endovascular revascularization (ER)
nd surgical revascularization (SR) for femoropopliteal occlusive disease.
Methods: Since 2004, 183 patients with femoropopliteal occlusive
isease had ER (85 [46%]) or SR (98 [54%]) for claudication (44% ER vs
6% SR, P NS) or chronic limb ischemia (56% ER vs 64% SR, P NS).
n amortized cost model that included patency data end points and all
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October 20111228 Abstractsdirect and indirect hospital costs of the initial and subsequent reinterven-
tions was applied to a prospectively collected vascular database. Analysis
was done via Student t test and log-ranked Kaplan-Meier analysis.
Results: The mean length in the ER group was 18.5 cm. A prosthetic
conduit was used in 51% of SR group. Patency at 1 year was similar in both groups
and superior for SR thereafter. The rate of all reinterventions was 28 of 85 (33%) in
ER and 40 of 98 (41%) in SR. The average hospital costs for the SR group were
significantly greater than costs for the ER group ($18,506 $,877 vs $11,740
$709, P  .005); however, this difference was not significant when comparing
amortized costs per day of patency at 1 year ($82 $21 vs $136 103), 2 years
($55$28 vs $152134), 3 years ($56 $44 vs $16 3), or 4 years ($8$1
vs $10 $2) in patients with claudication or chronic limb ischemia.
Conclusions: The amortized cost/day model is valuable for evaluating
resource utilization, enabling us to examine the cost efficacy of the proce-
dure, patency, and reinterventions. Our findings indicate that although
initially endovascular therapy for femoropopliteal occlusive disease is associ-
ated with significant savings, long term the amortized cost per day is
comparable in selected patients undergoing ER or SR.
Long-term Resource Utilization and Survival After Major Amputation
for Critical Limb Ischemia
Antonia J. Henry,1 Nathanael D. Hevelone,1 Michael T. Watkins,2 Michael
Belkin,1 Louis L. Nguyen,1 1Brigham and Women’s Hospital, Boston,
Mass; 2Massachusetts General Hospital, Boston, Mass
Introduction and objectives:Major amputation is associated with signif-
icant short-term health care resource utilization (RU), high mortality, and socio-
economicdisparities.Patient-specific and socioeconomic-relatedpredictorsof long-
term RU and survival after amputation have not been studied in detail.
Methods: Retrospective analysis identified 364 patients who underwent
primary major amputation for CLI from January 1995 to December 2000 at
two tertiary centers with outcomes through December 2010. Age, sex, race,
income, insurance, marital status, congestive heart failure (CHF), diabetes
mellitus (DM), complicated DM, renal failure, amputation level, additional
procedures, cumulative length of stay (cLOS), and mortality were analyzed.
Multivariate Poisson regression for additional procedures and cLOS, and Cox
proportional hazard modeling for all-cause mortality were undertaken.
Results:During amean follow-up of 3.25 years, patients hadmean cLOSof
37.4 days (median, 22), 5.54 readmissions (median, 4), 0.39 additional amputa-
tion-related procedures (median, 0), and 0.25 cardiovascular procedures (median,
0). Of readmissions 30 days, 52% were amputation-related. Mortality during
follow-up was 86.9%, with 37 patients (10.2%) dying 30 days. Among
those who survived 30 days, complicated DM, renal failure, and below
knee amputation were associated with additional amputation procedures.
CHF and renal failure were associated with a greater number of cardiovas-
cular procedures. Younger age, public insurance, being uninsured, CHF,
and renal failure were associated with increased cLOS. Older age, CHF,
renal failure, and undergoing above knee amputation decreased survival.
Race and income were not significantly related to the outcomes (Table).
Table. Outcomes after amputation
Outcome Incidence RR 95% CI P
Additional amputations
Variable
Complicated DM 1.897 1.085-3.317 .025
Renal failure 2.471 1.381-4.422 .002
Below knee amputation 2.425 1.103-5.331 .028
Outcome
Cardiovascular procedures
Variable
CHF 1.829 1.074-3.114 .026
Renal failure 3.669 2.309, 5.830 .0001
Cumulative LOS
Variable
Age 0.984 0.973-0.994 .002
Public insurance 1.627 1.166-2.269 .004
Uninsured 2.056 1.093-3.868 .025
CHF 1.605 1.123-2.293 .010
Renal failure 2.117 1.545, 2.900 .0001
Death
Variable Hazard ratio
Age 1.035 1.022-1.048 .0001
CHF 2.260 1.682-3.036 .0001
Renal failure 2.596 1.904-3.539 .0001
Above knee amputation 1.365 1.045-1.784 .023CHF, Congestive heart failure; CI, confidence interval; DM, diabetes mel-
litus; LOS, length of stay; RR, rate ratio.
a
mConclusions: Mortality and RU are high for amputees. Increased RU
ersists beyond the perioperative period. Results were similar across socio-
conomic groups, suggesting socioeconomic status does not predict RU
nce limb salvage is no longer attainable. Socioeconomic disparities may be
ore modifiable during earlier stages of CLI.
esion Characteristics that Predict Patency of Femoral Popliteal Endo-
ascular Intervention: A Novel Lesion Disease Severity Score
n-Kyong Kim, Egorova Natalia, Sikandar Z. Khan, Andrew J. Meltzer,
arry L. Bush, Jr, James F. McKinsey, New York-Presbyterian Hospital,
olumbia University, New York, NY
Introduction and objectives: Femoropopliteal artery occlusive le-
ion analysis was used to develop a comprehensive lesion severity score (LSS)
hat can predict patency after endovascular intervention (EVI).
able I. Independent factors predicting loss of patency
nd predictive factor score
Variablea Score
Cox
coefficient HR (95% CI) P
Diabetes 1 0.28 1.33 (1.05-1.68) .0159
Congestive heart
failure
1 0.29 1.35 (1.04-1.75) .0268
Lesion length
100 mm
2 0.46 1.59 (1.31-1.94) .001
Stenosis 80%-99% 2 0.35 1.42 (1.13-1.80) .0033
Chronic total
occlusion
3 0.56 1.76 (1.34-2.29) .001
I, Confidence interval; HR, hazard ratio.
Some factors not found not statistically significant were age, sex, weight,
ody mass index, renal disease, coronary artery disease, degree of calcifica-
ion, lesion length categories 100 mm, lesion stenosis 80%, tibial runoff
tatus.
able II. Patency based on lesion severity score (LSS)
LSS
Patency, % (95% CI)
6 months 12 months 24 months 36 months
0-1 89 (84-92) 81 (75-85) 71 (64-77) 69 (61-75)
2-3 82 (77-85) 68 (63-73) 57 (51-62) 51 (45-57)
4-5 76 (70-80) 55 (49-61) 41 (34-47) 32 (25-39)
6-7 71 (63-77) 44 (36-53) 26 (18-35) 15 (9-24)
Methods: A prospective database of all EVIs for femoropopliteal
esions from 2005 to 2009 was evaluated. Independent risk factors and
atency rates were analyzed by life-table analysis and Cox proportional
azards regression.
Results: Of 1776 lesions in our prospective database, 1329 were
iscrete femoropopliteal lesions in 675 patients (56.4% men; age, 72.4
ears). Analysis showed 17.5% of femoropopliteal lesions had a concomi-
antly treated tibial lesion. Among the 44 variables that were examined were
atient demographics and lesion characteristics, including degree of calcifi-
ation, length, and degree of stenosis of the lesion, chronic total occlusions,
nd the runoff status. Factors that predicted patency of lesions differed by
he location of the lesion. Only factors that independently predicted patency
pecifically for lesions of the femoral and popliteal artery were included in the
SS. The effect of each independent variable on patency was evaluated by
ox proportional hazards regression and assigned a score for the LSS (Table
). Patency after EVIs using the calculated LSS was assessed, and a strong
orrelation was revealed between the increasing LSS and significantly wors-
ning patency (Table II).
Conclusions: This novel LSS comprehensively combines patient co-
orbidities and lesion-specific factors in predicting long-term patency after
VI for the femoropopliteal vessels. Once further validated, this LSS will
llow for comprehensive comparison and classification of lesions and treat-
ent options even among multiple studies.
